文献速递糖尿病

NOD小鼠是1型糖尿病的良好模型吗?

Is the NOD mouse a good model for type 1 diabetes?
PubMed 文献 · Diabetologia · 2025-11-08

本文综述NOD小鼠作为1型糖尿病模型的价值,从历史视角讨论其在病因学、免疫发病机制和免疫治疗领域的贡献。文章比较了在NOD小鼠和人类中测试的免疫治疗制剂,指出非抗原特异性疗法转化更成功,而抗原特异性疗法并非如此,强调需恰当使用该模型。

要点

  • NOD小鼠是研究1型糖尿病病因和免疫发病机制的重要模型。
  • 非抗原特异性免疫疗法在NOD小鼠与人类间转化更有效,抗原特异性疗法不然。
  • 应恰当使用NOD小鼠模型,避免因不当比较或不现实期望而否定其价值。

核心结论

  • NOD小鼠是研究1型糖尿病的重要资源,但小鼠与人类存在必然差异,需恰当使用模型以最大化知识获取。

研究设计与样本

  • 综述,检索范围未明确报告。

主要发现

  • NOD小鼠在遗传学、胰岛β细胞应激、固有免疫和适应性免疫及自身抗原等方面提示了发现与知识。
  • 部分免疫治疗制剂(尤其非抗原特异性)在NOD小鼠和人类中转化更有效,抗原特异性疗法并非如此。

临床怎么用

  • 应合理利用NOD小鼠模型,避免因不恰当比较或不现实期望而否定该重要资源。

局限性

  • 小鼠与人类之间存在必然差异,模型信息外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The NOD mouse is the best-known, although by no means the only, murine model of type 1 diabetes. In this review, we provide a historical perspective, particularly highlighting areas of progress in understanding aspects of aetiology and immune pathogenesis, and utility in helping to shape the immunotherapeutic landscape. We introduce points of interest where the NOD mouse, a much-studied model, has signposted discovery and knowledge. We discuss genetics, pancreatic islet beta cell stress, innate and adaptive immunity and autoantigens, and also focus on immunotherapeutic agents that have been tested in NOD mice and in humans. Some therapies, particularly those that are non-antigen-specific, have been more effectively signposted, while others, which include antigen-specific therapies, have not. There is an inevitable divergence between mice and humans that illustrates the need to use models appropriately. We suggest how to make use of this and other models effectively in order to maximise information and knowledge, and suggest not dismissing this important resource because of inappropriate comparisons or unrealistic expectations.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Wong FS, Pearson JA, Wen L, et al. Is the NOD mouse a good model for type 1 diabetes? Diabetologia. 2025. PMID: 41206392. doi:10.1007/s00125-025-06579-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。